Qiagen NV (Qiagen NV) EBIT : $483 Mil (TTM As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV EBIT?

Qiagen NV's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $131 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $483 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Qiagen NV's annualized ROC % for the quarter that ended in Dec. 2023 was 8.64%. Qiagen NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 42.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Qiagen NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 5.05%.

Qiagen NV EBIT Historical Data

The historical data trend for Qiagen NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV EBIT Chart

Qiagen NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-3.59

510.79

680.31

570.96

483.22

Qiagen NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															120.71	123.24	115.81	112.85	131.32

Competitive Comparison of Qiagen NV's EBIT

For the Diagnostics & Research subindustry, Qiagen NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qiagen NV's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Qiagen NV's EV-to-EBIT falls into.

Qiagen NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $483 Mil.

Qiagen NV (NYSE:QGEN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Qiagen NV's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	485.96 * ( 1 - 17.84% )	/	( (4467.157	+	4772.818)	/ 2 )
=	399.264736	/	4619.9875
=	8.64 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5906.698	-	423.763	-	( 1015.778	-	max(0, 524.371	-	1962.39	+	1015.778	))
=	4467.157

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6115.19	-	284.59	-	( 1057.782	-	max(0, 1079.293	-	2147.56	+	1057.782	))
=	4772.818

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Qiagen NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	525.268	/	( ( (706.02 + max(522.849, 0))	+	(765.037 + max(486.957, 0)) )	/	2 )
=	525.268	/	( ( 1228.869	+	1251.994 )	/	2 )
=	525.268	/	1240.4315
=	42.35 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(326.69	+	399.207	+	220.715)	-	(423.763	+	0	+	0)
=	522.849

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(381.877	+	398.385	+	175.75)	-	(284.59	+	66.432	+	118.033)
=	486.957

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Qiagen NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	483.219	/	9567.610
	=	5.05 %

Qiagen NV EBIT Related Terms

Thank you for viewing the detailed overview of Qiagen NV's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Qiagen NV (Qiagen NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QIA:Germany QIA:Germany QGEN:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Executives